Ulrike Pötschger

Cancer Research Institute of the Slovak Academy of Sciences — SK

Medicine · Health Sciences

48h-index9.8kcitations179works2.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroblastoma Research and Treatments(59), Acute Lymphoblastic Leukemia research(41), Hematopoietic Stem Cell Transplantation(32), Childhood Cancer Survivors' Quality of Life(26), Histiocytic Disorders and Treatments(21)

Publications179 total

Supplementary Table S3 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial
2025Open Access
Supplementary Table S1 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial
2025Open Access
Supplementary Table S5 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial
2025Open Access
Supplementary Appendix S1 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial
2025Open Access
Supplementary Figure S5 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial
2025Open Access
Supplementary Figure S3 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial
2025Open Access
Supplementary Table S2 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial
2025Open Access
Supplementary Figure S4 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial
2025Open Access
Data from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial
2025Open Access
Supplementary Figure S1 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial
2025Open Access
Supplementary Table S4 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial
2025Open Access
Supplementary Figure S2 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial
2025Open Access
International neuroblastoma risk group consortium: a model of networking for rare cancers
JNCI Journal of the National Cancer Institute·2025· 2 citedOpen Access
Sensitive detection of minimal residual disease and immunotherapy targets by multi-modal bone marrow analysis in high-risk neuroblastoma – a multi-center study
Journal of Experimental & Clinical Cancer Research·2025· 1 citedOpen Access
Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial
Clinical Cancer Research·2025· 3 citedOpen Access
BRAFV600E induces key features of LCH in iPSCs with cell type–specific phenotypes and drug responses
Blood·2024· 9 citedOpen Access
Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL: results of FORUM
Blood Advances·2024· 2 citedOpen Access
Risk factors in DUX4-positive childhood and adolescent B-cell acute lymphoblastic leukemia
Blood Cancer Journal·2024· 5 citedOpen Access
Reproducibility Analysis of Radiomic Features on T2-weighted MR Images after Processing and Segmentation Alterations in Neuroblastoma Tumors
Radiology Artificial Intelligence·2024· 4 citedOpen Access
A human neural crest model reveals the developmental impact of neuroblastoma-associated chromosomal aberrations
Nature Communications·2024· 16 citedOpen Access
page 1 of 9Next →

Frequent Co-authors

Helmut Gadner(25), Ruth Ladenstein(14), Milen Minkov(14), Nicole Grois(12), Christina Peters(11), Dominique Valteau‐Couanet(9), Geneviève Laureys(9), Peter F. Ambros(9), Victoria Castel(8), Maja Beck‐Popovic(7), Jean Michon(6), Stephan Ladisch(6), Roberto Luksch(6), Ellen Ruud(6), Andrew D.J. Pearson(6), Michael Dworzak(6), Georg Mann(6), Maurizio Aricò(5), Jorge Braier(5), Isaac Yaniv(5)